Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2012, Article ID 583751, 6 pages
http://dx.doi.org/10.1100/2012/583751
Clinical Study

Central Precocious Puberty: Treatment with Triptorelin 11.25 mg

1Adolescent Medicine, I Pediatric Division, Department of Obstetrics, Gynecology and Pediatrics, Azienda Ospedaliero-Universitaria Pisana, 56126 Pisa, Italy
2Department of Gynecology, Obstetrics and Pediatrics, University of Bologna, 40138 Bologna, Italy
3Department of Pediatrics, University of Messina, 98124 Messina, Italy
4Department of Paediatrics, University of Florence, 50100 Florence, Italy
5Paediatric Endocrinology, Regina Margherita Children's Hospital, 10126 Turin, Italy
6Endocrinology Unit, Department University-Hospital, Bambino Gesù Children's Hospital, Tor Vergata University, 00165 Rome, Italy
7Pediatric and Adolescent Endocrinology, Department of Pediatrics, San Raffaele Scientific Institute, Vita-Salute S. Raffaele University, 20132 Milan, Italy

Received 9 October 2011; Accepted 22 December 2011

Academic Editor: Thomas E. Adrian

Copyright © 2012 Elena Chiocca et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. R. Larsen, H. M. Kronenberg, S. Melmed, and K. S. Polansky, “Puberty: ontogenety, Neuroendocrinology, physiology and disorders,” in Williams Textbook of Endocrinology, chapter 24, pp. 1115–1239, Saunders, Philadelphia, Pa, USA, 10th edition, 2003. View at Google Scholar
  2. J. C. Carel, E. A. Eugster, A. Rogol, L. Ghizzoni, and M. R. Palmert, “Consensus statement on the use of gonadotropin-releasing hormone analogs in children,” Pediatrics, vol. 138, pp. 752–762, 2009. View at Google Scholar
  3. N. Lahlou, J. C. Carel, J. L. Chaussain, and M. Roger, “Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics,” Journal of Pediatric Endocrinology and Metabolism, vol. 13, supplement 1, pp. 723–737, 2000. View at Google Scholar · View at Scopus
  4. S. Heger, M. Müller, M. Ranke et al., “Long-term GnRH agonist treatment for female central precocious puberty does not impair reproductive function,” Molecular and Cellular Endocrinology, vol. 254-255, pp. 217–220, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. O. Bouchot, J. Y. Soret, D. Jacqmin, N. Lahlou, M. Roger, and J. Blumberg, “Three-month sustained-release form of triptorelin in patients with advanced prostatic adenocarcinoma: results of an open pharmacodynamic and pharmacokinetic multicenter study,” Hormone Research, vol. 50, no. 2, pp. 89–93, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. J. C. Carel, N. Lahlou, O. Jaramillo et al., “Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg),” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 9, pp. 4111–4116, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. J. C. Carel, J. Blumberg, C. Seymour, C. Adamsbaum, and N. Lahlou, “Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty,” European Journal of Endocrinology, vol. 154, no. 1, pp. 119–124, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Martínez-Aguayo, M. I. Hernández, F. Beas et al., “Treatment of central precocious puberty with triptorelin 11.25 mg depot formulation,” Journal of Pediatric Endocrinology and Metabolism, vol. 19, no. 8, pp. 963–970, 2006. View at Google Scholar · View at Scopus
  9. A. Badaru, D. M. Wilson, L. K. Bachrach et al., “Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 5, pp. 1862–1867, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. V. Mericq, J. J. Lammoglia, N. Unanue et al., “Comparison of three doses of leuprolide acetate in the treatment of central precocious puberty: preliminary results,” Clinical Endocrinology, vol. 71, no. 5, pp. 686–690, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. E. Chiocca, E. Dati, G. I. Baroncelli et al., “Body mass index and body composition in adolescents treated with gonadotropin-releasing hormone analogue triptorelin depot for central precocious puberty: data at near final height,” Neuroendocrinology, vol. 89, no. 4, pp. 441–447, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. J. M. Tanner and R. H. Whitehouse, “Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty,” Archives of Disease in Childhood, vol. 51, no. 3, pp. 170–179, 1976. View at Google Scholar · View at Scopus
  13. W. W. Greulich and S. I. Pyle, Radiographic Atlas of Skeletal Development of the Hand and the Wrist, Stanford University Press, Stanford, Calif, USA, 2nd edition, 1959.
  14. N. Bayley and S. R. Pinneau, “Tables for predicting adult height from skeletal age: revised for use with the greulich-pyle hand standards,” The Journal of Pediatrics, vol. 40, no. 4, pp. 423–441, 1952. View at Google Scholar · View at Scopus
  15. T. J. Cole, M. C. Bellizzi, K. M. Flegal, and W. H. Dietz, “Establishing a standard definition for child overweight and obesity worldwide: international survey,” British Medical Journal, vol. 320, no. 7244, pp. 1240–1243, 2000. View at Google Scholar · View at Scopus
  16. M. C. Meriq, R. Y. Youlton, and Z. Willshaw, “Efectividad de la terapia con leuprolide acetate de deposito cada tres meses en pubertad precoz central,” Revue de Medicine Chile, vol. 134, pp. 821–826, 2006. View at Google Scholar
  17. J. A. Trueman, V. Tillmann, C. F. Cusick et al., “Suppression of puberty with long-acting goserelin (Zoladex-LA): effect on gonadotrophin response to GnRH in the first treatment cycle,” Clinical Endocrinology, vol. 57, no. 2, pp. 223–230, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Isaac, L. Patel, S. Meyer et al., “Efficacy of a monthly compared to 3-monthly depot GnRH analogue (goserelin) in the treatment of children with central precocious puberty,” Hormone Research, vol. 68, no. 4, pp. 157–163, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. K. A. Lewis and E. A. Eugster, “Experience with the once-yearly histrelin (GnRHa) subcutaneous implant in the treatment of central precocious puberty,” Drug Design, Development and Therapy, vol. 21, no. 3, pp. 1–5, 2009. View at Google Scholar · View at Scopus
  20. S. Rahhal, W. L. Clarke, G. B. Kletter et al., “Results of a second year of therapy with the 12-month histrelin implant for the treatment of central precocious puberty,” International Journal of Pediatric Endocrinology, vol. 2009, no. 1, Article ID 812517, 2009. View at Google Scholar
  21. R. Berges and U. Bello, “Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer,” Current Medical Research and Opinion, vol. 22, no. 4, pp. 649–655, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Donnez, P. J. Dewart, B. Hedon et al., “Equivalence of the 3-month and 28-day formulations of triptorelin with regard to achievement and maintenance of medical castration in women with endometriosis,” Fertility and Sterility, vol. 81, no. 2, pp. 297–304, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Fuld, C. Chi, and E. K. Neely, “A randomized trial of 1- and 3-month depot leuprolide doses in the treatment of central precocious puberty,” Journal of Pediatrics, vol. 159, no. 6, pp. 982–987, 2011. View at Publisher · View at Google Scholar
  24. K. L. Parker, R. G. Baens-Bailon, and P. A. Lee, “Depot leuprolide acetate dosage for sexual precocity,” Journal of Clinical Endocrinology and Metabolism, vol. 73, no. 1, pp. 50–52, 1991. View at Google Scholar · View at Scopus
  25. F. Massart, G. Federico, J. C. Harrell, and G. Saggese, “Growth outcome during gnrh agonist treatments for slowly progressive central precocious puberty,” Neuroendocrinology, vol. 90, no. 3, pp. 307–314, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. B. S. Miller and A. R. Shukla, “Sterile abscess formation in response to two separate branded long-acting gonadotropin-releasing hormone agonists,” Clinical Therapeutics, vol. 32, no. 10, pp. 1749–1751, 2010. View at Publisher · View at Google Scholar · View at Scopus